Health tech company H1 picked up an additional $33 million in funding after securing a hefty $100 million series C round just six months ago.
“In a time of volatile markets when many are struggling to secure funding, this extension is a vote of confidence in our ability to advance our mission. Our ability to raise capital at the same terms as our original series C close is a testament to our significant market opportunity and ability to execute against it,” said Ariel Katz, CEO and co-founder of H1.
The series C extension includes $23 million in equity financing and $10 million in debt financing, Katz told Fierce Healthcare. The new funding came from Goldman Sachs Asset Management, Menlo Ventures and Transformation Capital, which also invested in the first tranche of the round as well. Novartis Pharma AG also invested in the series C extension. The company has raised around $200 million to date.
RELATED: PBM Capital Rx raises $106M; Virtual surgery platform Proximie scores $80M
